keyword
MENU ▼
Read by QxMD icon Read
search

Luminal breast cancer

keyword
https://www.readbyqxmd.com/read/28076950/single-amino-acid-variant-profiles-of-subpopulations-in-the-mcf-7-breast-cancer-cell-line
#1
Zhijing Tan, Song Nie, Sean P McDermott, Max S Wicha, David M Lubman
Cancers are initiated and developed from a small population of stem-like cells termed cancer stem cells (CSCs). There is heterogeneity among this CSC population that leads to multiple subpopulations with their own distinct biological features and protein expression. The protein expression and function may be impacted by amino acid variants that can occur largely due to single nucleotide changes. We have thus performed proteomic analysis of breast CSC subpopulations by mass spectrometry to study the presence of single amino acid variants (SAAVs) and their relation to breast cancer...
January 11, 2017: Journal of Proteome Research
https://www.readbyqxmd.com/read/28076334/establishment-of-a-normal-derived-estrogen-receptor-positive-cell-line-comparable-to-the-prevailing-human-breast-cancer-subtype
#2
Branden M Hopkinson, Marie C Klitgaard, Ole William Petersen, René Villadsen, Lone Rønnov-Jessen, Jiyoung Kim
Understanding human cancer increasingly relies on insight gained from subtype specific comparisons between malignant and non-malignant cells. The most frequent subtype in breast cancer is the luminal. By far the most frequently used model for luminal breast cancer is the iconic estrogen receptor-positive (ERpos) MCF7 cell line. However, luminal specific comparisons have suffered from the lack of a relevant non-malignant counterpart. Our previous work has shown that transforming growth factor-β receptor (TGFβR) inhibition suffices to propagate prospectively isolated ERpos human breast luminal cells from reduction mammoplasties (HBEC)...
January 6, 2017: Oncotarget
https://www.readbyqxmd.com/read/28068979/first-report-on-molecular-breast-cancer-subtypes-and-their-clinico-pathological-characteristics-in-eastern-morocco-series-of-2260-cases
#3
Manal Elidrissi Errahhali, Mounia Elidrissi Errahhali, Meryem Ouarzane, Tijani El Harroudi, Said Afqir, Mohammed Bellaoui
BACKGROUND: Breast cancer is the most frequent malignancy among women in Eastern Morocco. In this paper, we provide the first report on molecular breast cancer subtypes in this region. This is the largest population-based study on breast cancer among Moroccan women. METHODS: We analyzed 2260 breast cancer cases diagnosed at the Hassan II Regional Oncology Center between October 2005 and December 2012. Clinico-pathological and therapeutic features were studied. Molecular subtypes were determined and their associations with the clinico-pathological characteristics of the tumors were examined...
January 9, 2017: BMC Women's Health
https://www.readbyqxmd.com/read/28068668/the-hippo-kinases-lats1-and-2-control-human-breast-cell-fate-via-crosstalk-with-er%C3%AE
#4
Adrian Britschgi, Stephan Duss, Sungeun Kim, Joana Pinto Couto, Heike Brinkhaus, Shany Koren, Duvini De Silva, Kirsten D Mertz, Daniela Kaup, Zsuzsanna Varga, Hans Voshol, Alexandra Vissieres, Cedric Leroy, Tim Roloff, Michael B Stadler, Christina H Scheel, Loren J Miraglia, Anthony P Orth, Ghislain M C Bonamy, Venkateshwar A Reddy, Mohamed Bentires-Alj
Cell fate perturbations underlie many human diseases, including breast cancer. Unfortunately, the mechanisms by which breast cell fate are regulated are largely unknown. The mammary gland epithelium consists of differentiated luminal epithelial and basal myoepithelial cells, as well as undifferentiated stem cells and more restricted progenitors. Breast cancer originates from this epithelium, but the molecular mechanisms that underlie breast epithelial hierarchy remain ill-defined. Here, we use a high-content confocal image-based short hairpin RNA screen to identify tumour suppressors that regulate breast cell fate in primary human breast epithelial cells...
January 9, 2017: Nature
https://www.readbyqxmd.com/read/28067435/mr-imaging-findings-in-molecular-subtypes-of-breast-cancer-according-to-birads-system
#5
Lidia Navarro Vilar, Salvador Pascual Alandete Germán, Rosana Medina García, Esther Blanc García, Natalia Camarasa Lillo, José Vilar Samper
To evaluate magnetic resonance imaging (MRI) findings, according to Breast Imaging-Reporting and Data System (BI-RADS), and to relate them with molecular subtypes of breast cancer. The MRI findings were reviewed retrospectively in 201 women diagnosed of invasive breast cancer confirmed by surgery and were compared with the molecular subtypes. Following the BI-RADS, MRI findings included disease type, size, enhancement, morphology and contrast kinetics. In mass-like lesion types were studied shape, margin and enhancement, and in nonmass-like lesion types, distribution modifiers and internal enhancement...
January 9, 2017: Breast Journal
https://www.readbyqxmd.com/read/28065398/molecular-subtypes-and-prognosis-in-young-mexican-women-with-breast-cancer
#6
Cynthia Villarreal-Garza, Alejandro Mohar, Juan Enrique Bargallo-Rocha, Federico Lasa-Gonsebatt, Nancy Reynoso-Noverón, Juan Matus-Santos, Paula Cabrera, Claudia Arce-Salinas, Fernando Lara-Medina, Alberto Alvarado-Miranda, María Teresa Ramírez-Ugalde, Enrique Soto-Perez-de-Celis
INTRODUCTION: Young age represents an adverse prognostic factor in breast cancer (BC), and young women present with more advanced and aggressive disease. In Latin America, BC is increasing in young women, and there is a lack of information regarding the characteristics and outcomes of this patient population. PATIENTS AND METHODS: We retrospectively analyzed a database of 4315 women treated for BC at a single institution. We compared clinical characteristics, treatment, and survival between women ≤ 40 and > 40 years of age...
November 23, 2016: Clinical Breast Cancer
https://www.readbyqxmd.com/read/28058578/pd-l1-expression-and-tumor-infiltrating-pd-1-%C3%A2-lymphocytes-associated-with-outcome-in-her2-%C3%A2-breast-cancer-patients
#7
Julia Y S Tsang, Wai-Ling Au, Kwan-Yin Lo, Yun-Bi Ni, Thazin Hlaing, Jintao Hu, Siu-Ki Chan, Kui-Fat Chan, Sai-Yin Cheung, Gary M Tse
PURPOSE: Clinical trials showing programmed death (PD)-1-PD-ligand 1 (L1) axis as a promising therapeutic target in melanoma and non-small cell lung cancers have made the pathway a focus of recent attention. However, the data regarding PD-L1/PD-1 in breast cancer are inconsistent. Given the heterogeneity of breast cancers, the clinical relevance of PD-L1 and PD-1 tumor infiltrating lymphocytes (TIL) may vary according to subtypes of breast cancer. We aim to investigate PD-L1 expression in a large cohort of breast cancers and analyze its clinico-pathological as well as outcome relationship according to molecular subtypes...
January 5, 2017: Breast Cancer Research and Treatment
https://www.readbyqxmd.com/read/28055972/integrative-genomic-and-transcriptomic-analysis-for-pinpointing-recurrent-alterations-of-plant-homeodomain-genes-and-their-clinical-significance-in-breast-cancer
#8
Huimei Yu, Yuanyuan Jiang, Lanxin Liu, Wenqi Shan, Xiaofang Chu, Zhe Yang, Zeng-Quan Yang
A wide range of the epigenetic effectors that regulate chromatin modification, gene expression, genomic stability, and DNA repair contain structurally conserved domains called plant homeodomain (PHD) fingers. Alternations of several PHD finger-containing proteins (PHFs) due to genomic amplification, mutations, deletions, and translocations have been linked directly to various types of cancer. However, little is known about the genomic landscape and the clinical significance of PHFs in breast cancer. Hence, we performed a large-scale genomic and transcriptomic analysis of 98 PHF genes in breast cancer using TCGA and METABRIC datasets and correlated the recurrent alterations with clinicopathological features and survival of patients...
December 31, 2016: Oncotarget
https://www.readbyqxmd.com/read/28052038/competing-endogenous-rna-network-analysis-identifies-critical-genes-among-the-different-breast-cancer-subtypes
#9
Juan Chen, Juan Xu, Yongsheng Li, Jinwen Zhang, Hong Chen, Jianping Lu, Zishan Wang, Xueying Zhao, Kang Xu, Yixue Li, Xia Li, Yan Zhang
Although competing endogenous RNAs (ceRNAs) have been implicated in many solid tumors, their roles in breast cancer subtypes are not well understood. We therefore generated a ceRNA network for each subtype based on the significance of both, positive co-expression and the shared miRNAs, in the corresponding subtype miRNA dys-regulatory network, which was constructed based on negative regulations between differentially expressed miRNAs and targets. All four subtype ceRNA networks exhibited scale-free architecture and showed that the common ceRNAs were at the core of the networks...
December 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/28052035/brca1-iris-overexpression-promotes-and-maintains-the-tumor-initiating-phenotype-implications-for-triple-negative-breast-cancer-early-lesions
#10
Abhilasha Sinha, Bibbin T Paul, Lisa M Sullivan, Hillary Sims, Ahmed El Bastawisy, Hend F Yousef, Abdel-Rahman N Zekri, Abeer A Bahnassy, Wael M ElShamy
Tumor-initiating cells (TICs) are cancer cells endowed with self-renewal, multi-lineage differentiation, increased chemo-resistance, and in breast cancers the CD44+/CD24-/ALDH1+ phenotype. Triple negative breast cancers show lack of BRCA1 expression in addition to enhanced basal, epithelial-to-mesenchymal transition (EMT), and TIC phenotypes. BRCA1-IRIS (hereafter IRIS) is an oncogene produced by the alternative usage of the BRCA1 locus. IRIS is involved in induction of replication, transcription of selected oncogenes, and promoting breast cancer cells aggressiveness...
December 29, 2016: Oncotarget
https://www.readbyqxmd.com/read/28050738/preoperative-neoadjuvant-chemotherapy-using-nanoparticle-albumin-bound-paclitaxel-followed-by-epirubicin-and-cyclophosphamide-for-operable-breast-cancer-a-multicenter-phase-ii-trial
#11
Manabu Futamura, Yasuko Nagao, Kazuhiro Ishihara, Makoto Takeuchi, Takumi Nakada, Yoshihiro Kawaguchi, Masayoshi Asano, Iwao Kumazawa, Takashi Shiroko, Kasumi Morimitsu, Ryutaro Mori, Masahito Nawa, Toshio Shimokawa, Kazuhiro Yoshida
BACKGROUND: Recently, the use of taxane-based regimens before anthracycline-based regimens has been shown to achieve high pathological complete response (pCR) rates in patients with breast cancer. Nanoparticle albumin-bound paclitaxel (nab-PTX) has been reported as highly effective and less toxic compared with Cremophor-based Taxol. This phase II clinical trial evaluated the safety and efficacy of preoperative neoadjuvant chemotherapy (NAC) with nab-PTX followed by an epirubicin plus cyclophosphamide (EC)-based regimen for operable breast cancer...
January 3, 2017: Breast Cancer: the Journal of the Japanese Breast Cancer Society
https://www.readbyqxmd.com/read/28049579/tumour-infiltrating-lymphocytes-and-the-emerging-role-of-immunotherapy-in-breast-cancer
#12
Stephen J Luen, Peter Savas, Stephen B Fox, Roberto Salgado, Sherene Loi
Breast cancer has not previously been considered a highly immunogenic cancer. Observations of tumour-infiltrating lymphocytes (TILs) in and around neoplastic cells in tumour samples, and associations with improved pathological complete response and clinical survival end points have changed our perspective on this. Lymphocytic infiltrates have long been observed in breast cancer; however, more recently, retrospective analysis of prospectively collected tissue samples from clinical trials has demonstrated the potential role of host immunosurveillance in influencing the biology of breast cancer...
December 31, 2016: Pathology
https://www.readbyqxmd.com/read/28045912/claudin-low-breast-cancer-clinical-pathological-characteristics
#13
Kay Dias, Anna Dvorkin-Gheva, Robin M Hallett, Ying Wu, John Hassell, Gregory R Pond, Mark Levine, Tim Whelan, Anita L Bane
Claudin-low breast cancer is a molecular type of breast cancer originally identified by gene expression profiling and reportedly associated with poor survival. Claudin-low tumors have been recognised to preferentially display a triple-negative phenotype, however only a minority of triple-negative breast cancers are claudin-low. We sought to identify an immunohistochemical profile for claudin-low tumors that could facilitate their identification in formalin fixed paraffin embedded tumor material. First, an in silico collection of ~1600 human breast cancer expression profiles was assembled and all claudin-low tumors identified...
2017: PloS One
https://www.readbyqxmd.com/read/28039701/the-maximum-standardized-uptake-value-of-metastatic-site-in-18-f-fdg-pet-ct-predicts-molecular-subtypes-and-survival-in-metastatic-breast-cancer-an-izmir-oncology-group-study
#14
Suna Cokmert, Ozgur Tanriverdi, Inanc Karapolat, Lutfiye Demir, Vedat Bayoglu, Alper Can, Murat Akyol, Yasar Yilmaz, Mustafa Oktay Tarhan
PURPOSE: The purpose of this study was to analyse the association between the 18F-2-deoxy-2-fluorodeoxyglucose maximum standardized uptake value (SUVmax) of metastatic sites and molecular subtypes and survival in metastatic breast cancer (MBC) patients. METHODS: Fluorine-18 fluorodeoxyglucose positron emission tomography/computed tomography (18F-FDG-PET/CT) was performed in 176 MBC patients before any therapeutic intervention. The FDG uptakes of metastatic sites were evaluated using the SUVmax...
November 2016: Journal of B.U.ON.: Official Journal of the Balkan Union of Oncology
https://www.readbyqxmd.com/read/28039357/key-survival-factor-mcl-1-correlates-with-sensitivity-to-combined-bcl-2-bcl-xl-blockade
#15
Michelle Williams, Linus Lee, Donna J Hicks, Meghan M Joly, David Elion, Bushra Rahman, Courtney McKernan, Violeta Sanchez, Justin M Balko, Thomas Stricker, Monica Valeria Estrada, Rebecca S Cook
: An estimated 40,000 deaths will be attributed to breast cancer in 2016, underscoring the need for improved therapies. Evading cell death is a major hallmark of cancer, driving tumor progression and therapeutic resistance. To evade apoptosis, cancers use anti-apoptotic Bcl-2 proteins to bind to and neutralize apoptotic activators, such as Bim. Investigation of anti-apoptotic Bcl-2 family members in clinical breast cancer datasets, revealed greater expression and more frequent gene amplification of MCL1 as compared to BCL2 or BCL2L1 (Bcl-xL) across three major molecular breast cancer subtypes, Luminal (A and B), HER2-enriched, and Basal-like...
December 30, 2016: Molecular Cancer Research: MCR
https://www.readbyqxmd.com/read/28039264/immunization-against-hif-1%C3%AE-inhibits-the-growth-of-basal-mammary-tumors-and-targets-mammary-stem-cells-in-vivo
#16
Denise L Cecil, Meredith Slota, Megan M O'Meara, Benjamin C Curtis, Ekram Gad, Yushe Dang, Daniel Herendeen, Lauren Rastetter, Mary L Disis
PURPOSE: Triple negative breast cancer (TNBC) represents a cancer stem cell enriched phenotype. Hypoxia-inducible factor-1 alpha (HIF-1α) induces the expression of proteins associated with stemness and is highly upregulated in TNBC. We questioned whether HIF-1α was immunogenic and whether vaccination targeting HIF-1α would impact the growth of basal-like mammary tumors in transgenic mice. EXPERIMENTAL DESIGN: We evaluated HIF-1α-specific IgG in sera from controls and patients with breast cancer...
December 30, 2016: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28039161/the-different-t-cell-receptor-repertoires-in-breast-cancer-tumors-draining-lymph-nodes-and-adjacent-tissues
#17
Ting Wang, Changxi Wang, Jinghua Wu, Chenyang He, Wei Zhang, Jiayun Liu, Ruifang Zhang, Yonggang Lv, Yongping Li, Xiaojing Zeng, Hongzhi Cao, Xiuqing Zhang, Xun Xu, Chen Huang, Ling Wang, Xiao Liu
T lymphocytes infiltrate the microenvironment of breast cancer (BC) tumors and play a pivotal role in tumor immune surveillance. Relationships between the T-cell receptors (TCRs) borne by T cells within tumors, in the surrounding tissues, and in draining lymph nodes are largely unexplored in human breast cancer. Consequently, information about the relative extent of possible T-cell exchange between these tissues is also lacking. Here we have analyzed the TCR repertoire of T cells using multiplex PCR and high throughput sequencing of the TCRβ chain in the tissues of tumor, adjacent nontumor, and axillary lymph-nodes of breast cancer patients...
December 30, 2016: Cancer Immunology Research
https://www.readbyqxmd.com/read/28033508/pathological-complete-response-in-invasive-breast-cancer-treated-by-skin-sparing-mastectomy-and-immediate-reconstruction-following-neoadjuvant-chemotherapy-and-radiation-therapy-comparison-between-immunohistochemical-subtypes
#18
J Barrou, M Bannier, M Cohen, E Lambaudie, A Gonçalves, P Bertrand, M Buttarelli, P Opinel, N Sterkers, A Tallet, C Zinzindohoué, G Houvenaeghel
CONTEXT: Even if neoadjuvant chemotherapy (NACT) and oncoplastic techniques have increased the breast conserving surgery rate, mastectomy is still a standard for multifocal or extensive breast cancers (BC). In the prospect of increasing breast reconstruction, an alternative therapeutic protocol was developed combining NACT with neoadjuvant radiation therapy (NART), followed by mastectomy with immediate breast reconstruction (IBR). The oncological safety of this therapeutic plan still needs further exploration...
December 26, 2016: Breast: Official Journal of the European Society of Mastology
https://www.readbyqxmd.com/read/28030809/genomic-regulation-of-invasion-by-stat3-in-triple-negative-breast-cancer
#19
Joy M McDaniel, Katherine E Varley, Jason Gertz, Daniel S Savic, Brian S Roberts, Sarah K Bailey, Lalita A Shevde, Ryne C Ramaker, Brittany N Lasseigne, Marie K Kirby, Kimberly M Newberry, E Christopher Partridge, Angela L Jones, Braden Boone, Shawn E Levy, Patsy G Oliver, Katherine C Sexton, William E Grizzle, Andres Forero, Donald J Buchsbaum, Sara J Cooper, Richard M Myers
Breast cancer is a heterogeneous disease comprised of four molecular subtypes defined by whether the tumor-originating cells are luminal or basal epithelial cells. Breast cancers arising from the luminal mammary duct often express estrogen receptor (ER), progesterone receptor (PR), and human epidermal growth receptor 2 (HER2). Tumors expressing ER and/or PR are treated with anti-hormonal therapies, while tumors overexpressing HER2 are targeted with monoclonal antibodies. Immunohistochemical detection of ER, PR, and HER2 receptors/proteins is a critical step in breast cancer diagnosis and guided treatment...
December 24, 2016: Oncotarget
https://www.readbyqxmd.com/read/28029685/immunoprofile-of-metaplastic-carcinomas-of-the-breast
#20
Emad A Rakha, Nuno D M Coimbra, Zsolt Hodi, Enaam Juneinah, Ian O Ellis, Andrew H S Lee
BACKGROUND: Metaplastic breast carcinoma (MBC) is a rare type of breast cancer and its diagnosis in routine practice can be challenging and may require immunohistochemical (IHC) characterisation if no conventional invasive or in situ carcinoma is present. Previous IHC studies of MBC often had a small sample size and did not investigate the different histological subtypes. This study aimed to assess the immunoprofile of MBC subtypes in a large series. METHODS: 172 MBC diagnosed in routine and referral practice in Nottingham over 26 years were reviewed by 3 breast pathologists...
December 28, 2016: Histopathology
keyword
keyword
63584
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"